FinscoFinsco

Coherus Oncology (US.CHRS)

Capital Allocation Audit · Period: 2012 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CHRS · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion100.0%→
ROE-96.9%↓
Cash Conversion-→
D/E Ratio0.65↓
Gross Margin69.7%↑
US.CHRS (Coherus Oncology) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   100.0%    →
ROE              -96.9%    ↓
Cash Conversion       -    →
D/E Ratio          0.65    ↓
Gross Margin      69.7%    ↑
Key Metrics
US.CHRS (Coherus Oncology) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 100.0% →
ROE -96.9% ↓
Cash Conversion - →
D/E Ratio 0.65 ↓
Gross Margin 69.7% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies